DOCSLIB.ORG

Toward Conventional Dendritic Cells Progenitors and Directs Subset

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toward Conventional Dendritic Cells Progenitors and Directs Subset The Journal of Immunology TGF-b1 Accelerates Dendritic Cell Differentiation from Common Dendritic Cell Progenitors and Directs Subset Specification toward Conventional Dendritic Cells Piritta Felker,*,† Kristin Sere´,*,† Qiong Lin,*,† Christiane Becker,*,† Mihail Hristov,‡ Thomas Hieronymus,*,† and Martin Zenke*,† Dendritic cells (DCs) in lymphoid tissue comprise conventional DCs (cDCs) and plasmacytoid DCs (pDCs) that develop from com- mon DC progenitors (CDPs). CDPs are Flt3+c-kitintM-CSFR+ and reside in bone marrow. In this study, we describe a two-step culture system that recapitulates DC development from c-kithiFlt32/lo multipotent progenitors (MPPs) into CDPs and further into cDC and pDC subsets. MPPs and CDPs are amplified in vitro with Flt3 ligand, stem cell factor, hyper–IL-6, and insulin-like growth factor-1. The four-factor mixture readily induces self-renewal of MPPs and their progression into CDPs and has no self- renewal activity on CDPs. The amplified CDPs respond to all known DC poietins and generate all lymphoid tissue DCs in vivo and in vitro. Additionally, in vitro CDPs recapitulate the cell surface marker and gene expression profile of in vivo CDPs and possess a DC-primed transcription profile. TGF-b1 impacts on CDPs and directs their differentiation toward cDCs. Genome-wide gene expression profiling of TGF-b1–induced genes identified instructive transcription factors for cDC subset specification, such as IFN regulatory factor-4 and RelB. TGF-b1 also induced the transcription factor inhibitor of differentiation/DNA binding 2 that suppresses pDC development. Thus, TGF-b1 directs CDP differentiation into cDCs by inducing both cDC instructive factors and pDC inhibitory factors. The Journal of Immunology, 2010, 185: 5326–5335. + + + endritic cells (DCs) are professional APCs that are im- DC progenitors were described: a Flt3 c-kit CX3CR1 macrophage/ portant in inducing adaptive immune responses and main- DC progenitor (MDP) (7, 8) and an Flt3+c-kitintM-CSFR+ com- D taining T cell tolerance (1–3). DCs are divided into mon DC progenitor (CDP) (9, 10). MDPs give rise to macrophages several subsets according to their localization, phenotype, and and DCs, whereas CDPs are DC-restricted and do not generate other function. The main DC subsets are conventional DCs (cDCs) and cell types. Indeed, MDPs were shown to be more heterogeneous and plasmacytoid DCs (pDCs) found in lymphoid organs and migra- to contain CDPs (8, 11, 12). tory tissue DCs that are spread throughout peripheral organs (2, Frequently, DCs are generated from bone marrow or cord blood- by guest on September 30, 2021. Copyright 2010 Pageant Media Ltd. 3). DC development shows remarkable plasticity, and DCs have derived hematopoietic stem/progenitor cells or blood monocytes been shown to develop from both lymphoid and myeloid compart- in vitro. The major cytokines used in culturing DCs are Flt3 ligand ments via Flt3-expressing progenitors (4–6). Recently, clonogenic (Flt3L) and GM-CSF, and, more recently, M-CSF (13–17). Flt3L and M-CSF cultures give rise to cDC and pDC subsets, whereas hi *Department of Cell Biology, Institute for Biomedical Engineering, †Helmholtz In- GM-CSF induces the differentiation of CD11b DCs. According to stitute for Biomedical Engineering, and ‡Institute for Molecular Cardiovascular Re- the current view, Flt3L-generated DCs are considered as in vitro search, Medical Faculty, Rheinisch-Westfa¨lische Technische Hochschule, Aachen, Germany equivalents of steady state DCs, as found, for example, in spleen. Flt3L is the major cytokine for DC development in steady state Received for publication December 8, 2009. Accepted for publication August 20, 2010. in vivo; Flt3L is a potent inducer of both cDCs and pDCs in human https://www.jimmunol.org This work was supported by Grants SFB542 and SPP1356 from the German Research and mouse (15, 18, 19). Accordingly, Flt3L-deficient mice have Foundation (to M.Z.). a severe reduction in DC numbers in several lymphoid organs (15, 20, The microarray data presented in this article have been submitted to the Gene Ex- 21). Interestingly, administration of M-CSF induces cDC and pDC pression Omnibus database (http://www.ncbi.nlm.nih.gov/geo) under accession num- generation in vivo (17), and M-csf–deficient (CSF-1op/op)micehave ber GSE22432. reduced numbers of splenic DCs (22), indicating the in vivo rele- Address correspondence and reprint requests to Dr. Martin Zenke, Department of Cell Biology, Institute for Biomedical Engineering, Medical Faculty, Rheinisch- vance of M-CSF in DC development. In contrast, GM-CSF induces Downloaded from Westfa¨lische Technische Hochschule Aachen, Pauwelsstrasse 30, 52074 Aachen, differentiation of inflammatory DCs that have no steady-state Germany. E-mail address: [email protected] counterpart in vivo. GM-CSF appears to be involved in MDP and The online version of this article contains supplemental material. CDP homeostasis in bone marrow as well as in nonlymphoid tissue Abbreviations used in this paper: C, negative control; cDC, conventional dendritic cell; dermal DC development (21). However, Gm-csf– and Gm-csfr– CDP, common dendritic cell progenitor; CFU-G, CFU granulocyte; CFU-GEMM, deficient mice have only a very mild reduction in DC numbers in CFU granulocyte, erythrocyte, macrophage, megakaryocyte; CFU-GM, CFU granulo- cyte/macrophage; CFU-M, CFU macrophage; DC, dendritic cell; Flt3L, Flt3 ligand; lymphoid tissues where Flt3L is the more crucial factor (21, 23). GEMM, granulocyte, erythrocyte, macrophage, megakaryocyte; GO, Gene Ontology; TGF-b1 is a pleiotropic cytokine involved in a variety of bio- HLH, helix-loop-helix; HSC, hematopoietic stem cell; Id2, inhibitor of differentiation/ DNA binding 2; IGF-1, insulin-like growth factor-1; IRF, IFN regulatory factor; MDP, logical processes, such as development, differentiation, apoptosis, macrophage/DC progenitor; MHC-II, MHC class II; MPP, multipotent progenitor; and cell survival (24). TGF-b1 is crucial for development of PCA, principal component analysis; pDC, plasmacytoid dendritic cell; PI, propidium Langerhans cells, the cutaneous contingent of migratory DC, both iodide; SCF, stem cell factor. in vivo and in vitro (25–27). Yet, the influence of TGF-b1on Copyright Ó 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00 development of other DC subsets is so far unknown. www.jimmunol.org/cgi/doi/10.4049/jimmunol.0903950 The Journal of Immunology 5327 The current understanding of DC development is mainly based Flow cytometry and cell sorting on studies of genetically modified mice and knockout models that Abs directly conjugated to biotin, FITC, PE, PE-Cy5, PerCP-Cy5.5, PE- lack transcription factors (reviewed in Refs. 3, 28, and 29). STAT3 Cy7, allophycocyanin, or Pacific Blue specific for the following Ags were is a central transcription factor in Flt3 signaling, and deletion used: AA4.1/CD93/Ly68 (AA4.1), B220 (RA3-6B2), CD3ε (145-2C11), of STAT3 severely impairs DC development (30). PU.1, an Ets CD4 (GK1.5), CD8a (53-6.7), CD11b (M1/70), CD11c (N418 or HL3), family transcription factor, is expressed highly in hematopoetic CD19 (1D3), CD24 (M1/69), CD45.1 (A20), CD45.2 (104), CD115 (AFS98), CD117 (ACK2), CD127 (A7R34), CD135 (A2F10.1), Gr-1 progenitors and DCs (31). Mice reconstituted with Pu.1-deficient (RB6-C5), MHC class II (MHC-II; M5/114.15.2), PDCA-1 (JF05- hematopoietic cells have severe hematopoietic defects and lack 1C2.4.1), Sca-1 (D7), SiglecH (440c), and Ter119/Ly-76 (TER-119) (all cDCs (32, 33). Ikaros, a zinc finger transcriptional regulator, is from BD Biosciences, San Jose, CA; eBioscience, San Diego, CA; or required for the normal development of early hematopoietic pro- Miltenyi Biotec, Bergisch Gladbach, Germany). Pacific Blue-labeled F4/80 (Cl:A3-1) Ab was from AbD Serotec (Du¨sseldorf, Germany). Purified genitors (34). Ikaros deficiency leads to either the ablation of all CD49d (R1-2) and CD49f (GoH3) Abs were from BD Biosciences. DC subsets or the absence of specific DC subsets, which depends Lineage-positive cells were stained with biotin-conjugated Lineage Cell on the type of mutation introduced (35, 36). Other transcription Detection Cocktail (Miltenyi Biotec). Streptavidin-FITC, streptavidin-PE, factors have a more selected impact on DC subset specification. and streptavidin-allophycocyanin were from Invitrogen or eBioscience. The development of cDCs is influenced by the IFN regulatory Streptavidin-PerCP-Cy5.5 was from BD Biosciences. Secondary goat anti- rat Ab conjugated to PE was from Invitrogen. Cells were treated with anti- factors (IRFs) IRF-2, IRF-4, and IRF-8 (also known as ICSBP) FcR–blocking reagent (Miltenyi Biotec) and 3% mouse serum prestaining. (37), the helix-loop-helix (HLH) transcription factor inhibitor of differentiation/DNA binding 2 (Id2) (38), and the NF-kB/Rel family member RelB (39, 40), among others. pDC development depends on the basic HLH factor E2-2 (41, 42), the Ets-domain transcription factor Spi-B (43), and IRF-4 and IRF-8 (37). Al- though critically adding to our understanding of DC development, it is worthwhile to note that these studies so far concentrated on the phenotype in mature DCs. It is yet unclear at which stage and how these factors influence DC development. In this study, we investigated the early steps of DC develop- ment from multipotent progenitors (MPPs) and CDPs, and the impact of TGF-b1 on DC subset specification from CDPs. CDPs are very scarce cells in vivo; thus, we used an in vitro culture sys- tem to obtain high numbers of CDPs. We show consecutive dif- ferentiation of MPPs to CDPs and further to DC subtypes and provide functional and molecular analyses of this differentiation pathway. We also demonstrate that TGF-b1 accelerates DC dif- ferentiation and directs differentiation toward cDCs by inducing a cDC-affiliated transcription profile in CDPs. by guest on September 30, 2021. Copyright 2010 Pageant Media Ltd. Materials and Methods Mice C57BL/6 mice, CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ), GFP transgenic mice (44), and CX3CR1-GFP knockin mice (45) were maintained under specific pathogen-free conditions in the central animal facility of RWTH Aachen University Hospital, Aachen, Germany.
Load more

Recommended publications
  • Activated Peripheral-Blood-Derived Mononuclear Cells
    Transcription factor expression in lipopolysaccharide- activated peripheral-blood-derived mononuclear cells Jared C. Roach*†, Kelly D. Smith*‡, Katie L. Strobe*, Stephanie M. Nissen*, Christian D. Haudenschild§, Daixing Zhou§, Thomas J. Vasicek¶, G. A. Heldʈ, Gustavo A. Stolovitzkyʈ, Leroy E. Hood*†, and Alan Aderem* *Institute for Systems Biology, 1441 North 34th Street, Seattle, WA 98103; ‡Department of Pathology, University of Washington, Seattle, WA 98195; §Illumina, 25861 Industrial Boulevard, Hayward, CA 94545; ¶Medtronic, 710 Medtronic Parkway, Minneapolis, MN 55432; and ʈIBM Computational Biology Center, P.O. Box 218, Yorktown Heights, NY 10598 Contributed by Leroy E. Hood, August 21, 2007 (sent for review January 7, 2007) Transcription factors play a key role in integrating and modulating system. In this model system, we activated peripheral-blood-derived biological information. In this study, we comprehensively measured mononuclear cells, which can be loosely termed ‘‘macrophages,’’ the changing abundances of mRNAs over a time course of activation with lipopolysaccharide (LPS). We focused on the precise mea- of human peripheral-blood-derived mononuclear cells (‘‘macro- surement of mRNA concentrations. There is currently no high- phages’’) with lipopolysaccharide. Global and dynamic analysis of throughput technology that can precisely and sensitively measure all transcription factors in response to a physiological stimulus has yet to mRNAs in a system, although such technologies are likely to be be achieved in a human system, and our efforts significantly available in the near future. To demonstrate the potential utility of advanced this goal. We used multiple global high-throughput tech- such technologies, and to motivate their development and encour- nologies for measuring mRNA levels, including massively parallel age their use, we produced data from a combination of two distinct signature sequencing and GeneChip microarrays.
    [Show full text]
  • An Animal Model with a Cardiomyocyte-Specific Deletion of Estrogen Receptor Alpha: Functional, Metabolic, and Differential Netwo
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 An animal model with a cardiomyocyte-specific deletion of estrogen receptor alpha: Functional, metabolic, and differential network analysis Sriram Devanathan Washington University School of Medicine in St. Louis Timothy Whitehead Washington University School of Medicine in St. Louis George G. Schweitzer Washington University School of Medicine in St. Louis Nicole Fettig Washington University School of Medicine in St. Louis Attila Kovacs Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Devanathan, Sriram; Whitehead, Timothy; Schweitzer, George G.; Fettig, Nicole; Kovacs, Attila; Korach, Kenneth S.; Finck, Brian N.; and Shoghi, Kooresh I., ,"An animal model with a cardiomyocyte-specific deletion of estrogen receptor alpha: Functional, metabolic, and differential network analysis." PLoS One.9,7. e101900. (2014). https://digitalcommons.wustl.edu/open_access_pubs/3326 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Sriram Devanathan, Timothy Whitehead, George G. Schweitzer, Nicole Fettig, Attila Kovacs, Kenneth S. Korach, Brian N. Finck, and Kooresh I. Shoghi This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/3326 An Animal Model with a Cardiomyocyte-Specific Deletion of Estrogen Receptor Alpha: Functional, Metabolic, and Differential Network Analysis Sriram Devanathan1, Timothy Whitehead1, George G. Schweitzer2, Nicole Fettig1, Attila Kovacs3, Kenneth S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Paracrine Activation of WNT/Β-Catenin Pathway in Uterine Leiomyoma Stem Cells Promotes Tumor Growth
    Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth Masanori Onoa,b, Ping Yina, Antonia Navarroa, Molly B. Moraveka, John S. Coon Va, Stacy A. Druschitza, Vanida Ann Sernaa, Wenan Qianga, David C. Brooksa, Saurabh S. Malpania, Jiajia Maa, Cihangir Mutlu Ercana, Navdha Mittala, Diana Monsivaisa, Matthew T. Dysona, Alex Yemelyanovc, Tetsuo Maruyamab, Debabrata Chakravartia, J. Julie Kima, Takeshi Kuritaa, Cara J. Gottardic, and Serdar E. Buluna,1 Departments of aObstetrics and Gynecology and cMedicine, Feinberg School of Medicine at Northwestern University, Chicago, IL 60611; and bDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Shinjuku, Tokyo 160-8582, Japan Edited by Jan-Åke Gustafsson, University of Houston, Houston, Texas, and approved September 5, 2013 (received for review July 18, 2013) Uterine leiomyomas are extremely common estrogen and proges- somatic stem cells and has been used to isolate them from many terone-dependent tumors of the myometrium and cause irregular adult tissues, such as the myometrium, endometrium, and mam- – uterine bleeding, severe anemia, and recurrent pregnancy loss in mary gland (9 12). We and another group have reported that SP 15–30% of reproductive-age women. Each leiomyoma is thought cells from human LM exhibit key features of the tumor-initiating to arise from a single mutated myometrial smooth muscle stem cells (13, 14). It has been proposed that each LM originates from a single cell. Leiomyoma side-population (LMSP) cells comprising 1% of all transformed somatic stem cell of the myometrium in an ovarian tumor cells and displaying tumor-initiating stem cell characteristics steroid-dependent manner (15); however, this suggestion has not are essential for estrogen- and progesterone-dependent in vivo been proven definitively.
    [Show full text]
  • E Proteins and ID Proteins: Helix-Loop-Helix Partners in Development and Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Developmental Cell Review E Proteins and ID Proteins: Helix-Loop-Helix Partners in Development and Disease Lan-Hsin Wang1 and Nicholas E. Baker1,2,3,* 1Department of Genetics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA 2Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA 3Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.devcel.2015.10.019 The basic Helix-Loop-Helix (bHLH) proteins represent a well-known class of transcriptional regulators. Many bHLH proteins act as heterodimers with members of a class of ubiquitous partners, the E proteins. A widely expressed class of inhibitory heterodimer partners—the Inhibitor of DNA-binding (ID) proteins—also exists. Genetic and molecular analyses in humans and in knockout mice implicate E proteins and ID proteins in a wide variety of diseases, belying the notion that they are non-specific partner proteins. Here, we explore relationships of E proteins and ID proteins to a variety of disease processes and highlight gaps in knowledge of disease mechanisms. E proteins and Inhibitor of DNA-binding (ID) proteins are widely conferring DNA-binding specificity and transcriptional activation expressed transcriptional regulators with very general functions. on heterodimers with the ubiquitous E proteins (Figure 1). They are implicated in diseases by evidence ranging from Another class of pervasive HLH proteins acts in opposition to confirmed Mendelian inheritance, association studies, and E proteins.
    [Show full text]
  • Xenobiotic-Sensing Nuclear Receptors Involved in Drug Metabolism: a Structural Perspective
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Drug Metab Manuscript Author Rev. Author Manuscript Author manuscript; available in PMC 2016 May 24. Published in final edited form as: Drug Metab Rev. 2013 February ; 45(1): 79–100. doi:10.3109/03602532.2012.740049. Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective Bret D. Wallace and Matthew R. Redinbo Departments of Chemistry, Biochemistry, and Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Abstract Xenobiotic compounds undergo a critical range of biotransformations performed by the phase I, II, and III drug-metabolizing enzymes. The oxidation, conjugation, and transportation of potentially harmful xenobiotic and endobiotic compounds achieved by these catalytic systems are significantly regulated, at the gene expression level, by members of the nuclear receptor (NR) family of ligand-modulated transcription factors. Activation of NRs by a variety of endo- and exogenous chemicals are elemental to induction and repression of drug-metabolism pathways. The master xenobiotic sensing NRs, the promiscuous pregnane X receptor and less-promiscuous constitutive androstane receptor are crucial to initial ligand recognition, jump-starting the metabolic process. Other receptors, including farnesoid X receptor, vitamin D receptor, hepatocyte nuclear factor 4 alpha, peroxisome proliferator activated receptor, glucocorticoid receptor, liver X receptor, and RAR-related orphan receptor, are not directly linked to promiscuous xenobiotic binding, but clearly play important roles in the modulation of metabolic gene expression. Crystallographic studies of the ligand-binding domains of nine NRs involved in drug metabolism provide key insights into ligand-based and constitutive activity, coregulator recruitment, and gene regulation.
    [Show full text]
  • Open Chromatin Profiling in Adipose Tissue Marks Genomic Regions with Functional Roles in Cardiometabolic Traits
    INVESTIGATION Open Chromatin Profiling in Adipose Tissue Marks Genomic Regions with Functional Roles in Cardiometabolic Traits Maren E. Cannon,*,1 Kevin W. Currin,*,1 Kristin L. Young,† Hannah J. Perrin,* Swarooparani Vadlamudi,* Alexias Safi,‡ Lingyun Song,‡ Ying Wu,* Martin Wabitsch,§ Markku Laakso,** Gregory E. Crawford,‡ and Karen L. Mohlke*,2 *Department of Genetics, †Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, ‡Department of Pediatrics, Division of Medical Genetics and Center for Genomic and Computational Biology, § Duke University, NC 27710, Department of Pediatrics and Adolescents Medicine, Division of Pediatric Endocrinology and Diabetes, University of Ulm, Germany 89081, and **Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland 70210 ORCID ID: 0000-0001-6721-153X (K.L.M.) ABSTRACT Identifying the regulatory mechanisms of genome-wide association study (GWAS) loci KEYWORDS affecting adipose tissue has been restricted due to limited characterization of adipose transcriptional chromatin regulatory elements. We profiled chromatin accessibility in three frozen human subcutaneous adipose accessibility tissue needle biopsies and preadipocytes and adipocytes from the Simpson Golabi-Behmel Syndrome adipose tissue (SGBS) cell strain using an assay for transposase-accessible chromatin (ATAC-seq). We identified preadipocytes 68,571 representative accessible chromatin regions (peaks) across adipose tissue samples (FDR , 5%). GWAS GWAS loci for eight cardiometabolic traits were enriched in these peaks (P , 0.005), with the strongest cardiometabolic enrichment for waist-hip ratio. Of 110 recently described cardiometabolic GWAS loci colocalized with trait adiposetissueeQTLs,59locihadoneormorevariantsoverlappinganadiposetissuepeak.Annotated variants at the SNX10 waist-hip ratio locus and the ATP2A1-SH2B1 body mass index locus showed allelic differences in regulatory assays.
    [Show full text]
  • Lineage Transcription Factors Co-Regulate Subtype-Specific Genes Providing a Roadmap For
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.13.249029; this version posted August 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Lineage transcription factors co-regulate subtype-specific genes providing a roadmap for systematic identification of small cell lung cancer vulnerabilities Karine Pozo1,2, Rahul K. Kollipara3, Demetra P. Kelenis1, Kathia E. Rodarte1, Xiaoyang Zhang4, John D. Minna5,6,7,8 and Jane E. Johnson1,6,8 1Department of Neuroscience, 2Department of Surgery, 3McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX 75390, USA 4Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 5Hamon Center for Therapeutic Oncology Research, 6Simmons Comprehensive Cancer Center, 7Department of Internal Medicine, 8Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA JDM receives licensing fees for lung cancer lines from the NIH and UT Southwestern. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.13.249029; this version posted August 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. ABSTRACT Lineage-defining transcription factors (LTFs) play key roles in tumor cell growth, making them highly attractive, but currently “undruggable”, small cell lung cancer (SCLC) vulnerabilities.
    [Show full text]
  • SUMO and Transcriptional Regulation: the Lessons of Large-Scale Proteomic, Modifomic and Genomic Studies
    molecules Review SUMO and Transcriptional Regulation: The Lessons of Large-Scale Proteomic, Modifomic and Genomic Studies Mathias Boulanger 1,2 , Mehuli Chakraborty 1,2, Denis Tempé 1,2, Marc Piechaczyk 1,2,* and Guillaume Bossis 1,2,* 1 Institut de Génétique Moléculaire de Montpellier (IGMM), University of Montpellier, CNRS, Montpellier, France; [email protected] (M.B.); [email protected] (M.C.); [email protected] (D.T.) 2 Equipe Labellisée Ligue Contre le Cancer, Paris, France * Correspondence: [email protected] (M.P.); [email protected] (G.B.) Abstract: One major role of the eukaryotic peptidic post-translational modifier SUMO in the cell is transcriptional control. This occurs via modification of virtually all classes of transcriptional actors, which include transcription factors, transcriptional coregulators, diverse chromatin components, as well as Pol I-, Pol II- and Pol III transcriptional machineries and their regulators. For many years, the role of SUMOylation has essentially been studied on individual proteins, or small groups of proteins, principally dealing with Pol II-mediated transcription. This provided only a fragmentary view of how SUMOylation controls transcription. The recent advent of large-scale proteomic, modifomic and genomic studies has however considerably refined our perception of the part played by SUMO in gene expression control. We review here these developments and the new concepts they are at the origin of, together with the limitations of our knowledge. How they illuminate the SUMO-dependent Citation: Boulanger, M.; transcriptional mechanisms that have been characterized thus far and how they impact our view of Chakraborty, M.; Tempé, D.; SUMO-dependent chromatin organization are also considered.
    [Show full text]
  • A Small-Molecule Antagonist of the B-Catenin/ TCF4 Interaction Blocks
    Published OnlineFirst December 8, 2015; DOI: 10.1158/0008-5472.CAN-15-1519 Cancer Therapeutics, Targets, and Chemical Biology Research A Small-Molecule Antagonist of the b-Catenin/ TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis Liang Fang1, Qionghua Zhu1, Martin Neuenschwander2, Edgar Specker2, Annika Wulf-Goldenberg3, William I. Weis4, Jens P. von Kries2, and Walter Birchmeier1 Abstract Wnt/b-catenin signaling is a highly conserved pathway essen- high Wnt activity. LF3 also suppressed features of cancer cells tial for embryogenesis and tissue homeostasis. However, dereg- related to Wnt signaling, including high cell motility, cell-cycle ulation of this pathway can initiate and promote human malig- progression, and the overexpression of Wnt target genes. How- nancies, especially of the colon and head and neck. Therefore, ever, LF3 did not cause cell death or interfere with cadherin- Wnt/b-catenin signaling represents an attractive target for can- mediated cell–cell adhesion. Remarkably, the self-renewal capac- cer therapy. We performed high-throughput screening using ity of cancer stem cells was blocked by LF3 in concentration- AlphaScreen and ELISA techniques to identify small molecules dependent manners, as examined by sphere formation of colon that disrupt the critical interaction between b-catenin and the and head and neck cancer stem cells under nonadherent condi- transcription factor TCF4 required for signal transduction. We tions. Finally, LF3 reduced tumor growth and induced differen- found that compound LF3, a 4-thioureido-benzenesulfonamide tiation in a mouse xenograft model of colon cancer. Collectively, derivative, robustly inhibited this interaction. Biochemical assays our results strongly suggest that LF3 is a specific inhibitor of revealed clues that the core structure of LF3 was essential for canonical Wnt signaling with anticancer activity that warrants inhibition.
    [Show full text]
  • TCF4 Gene Transcription Factor 4
    TCF4 gene transcription factor 4 Normal Function The TCF4 gene provides instructions for making a protein that attaches (binds) to specific regions of DNA and helps control the activity of many other genes. On the basis of this action, the TCF4 protein is known as a transcription factor. The TCF4 protein is part of a group of proteins known as E-proteins. E-proteins each bind with another identical or similar protein and then bind to a specific sequence of DNA known as an E- box. E-proteins are involved in many aspects of development. The TCF4 protein is found in the brain, muscles, lungs, and heart. This protein also appears to be active (expressed) in various tissues before birth. The TCF4 protein plays a role in the maturation of cells to carry out specific functions (cell differentiation) and the self-destruction of cells (apoptosis). Health Conditions Related to Genetic Changes Pitt-Hopkins syndrome At least 50 mutations in the TCF4 gene have been found to cause Pitt-Hopkins syndrome, a condition characterized by severe intellectual disability and breathing problems. Some mutations delete a few building blocks of DNA (nucleotides) within the TCF4 gene, while other mutations delete the TCF4 gene as well as a number of genes that surround it. Still other TCF4 gene mutations replace single nucleotides. The type of the mutation does not appear to affect the severity of the condition. TCF4 gene mutations disrupt the protein's ability to bind to DNA and control the activity of certain genes. These gene mutations typically do not affect the TCF4 protein's ability to bind to other proteins.
    [Show full text]
  • Molecular Response to Aromatase Inhibitor Treatment in Primary Breast
    Available online http://breast-cancer-research.com/content/9/3/R37 ResearchVol 9 No 3 article Open Access Molecular response to aromatase inhibitor treatment in primary breast cancer Alan Mackay1*, Ander Urruticoechea2*, J Michael Dixon4, Tim Dexter1, Kerry Fenwick1, Alan Ashworth1, Suzanne Drury2, Alexey Larionov3, Oliver Young3, Sharon White3, William R Miller3, Dean B Evans4 and Mitch Dowsett1,2 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK 2Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK 3The Edinburgh Breast Unit, Western General Hospital, Edinburgh, EH4 2XU, UK 4Novartis Pharma AG, Basel, Switzerland * Contributed equally Corresponding author: Alan Mackay, [email protected] Received: 31 Jan 2007 Revisions requested: 8 Mar 2007 Revisions received: 26 Apr 2007 Accepted: 7 Jun 2007 Published: 7 Jun 2007 Breast Cancer Research 2007, 9:R37 (doi:10.1186/bcr1732) This article is online at: http://breast-cancer-research.com/content/9/3/R37 © 2007 Mackay et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background Aromatase inhibitors such as anastrozole and genes were particularly prominent. Many upregulated genes are letrozole are highly effective suppressants of estrogen synthesis involved in extracellular matrix remodelling, including collagens in postmenopausal women and are the most effective endocrine and members of the small leucine-rich proteoglycan family treatments for hormone receptor positive breast cancer in such (LUM, DCN, and ASPN).
    [Show full text]